Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared on LinkedIn:
“Any improvement in cancer care starts from measuring. In our latest JNCI article, we measure one of the greatest unmet needs in breast oncology: recurrences from HR+/HER2- breast cancer.
With a cohort of >7000 patients (Flatiron database), we report 7-year recurrence rates of 14% for N1 and N0 high-risk disease and up to ~40% in N2-3 disease. This is unfortunate, as too many of such recurrences lead to hard-to-treat metastatic disease.
The good news, though: we now have tools able to decrease such risk, i.e. adjuvant CDK4/6 inhibitors, and, possibly soon, oral SERDs.
Implementing such tools in practice will be imperative to see the advancements observed in clinical trials reflected in our real-world patients in the years to come.”
Title: Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health records study
Authors: Paolo Tarantino, Giuseppe Curigliano, Erika Hamilton, Julia Kim, Stephanie L. Graff, Patrick Neven, Ilana Schlam, Nadia Harbeck, Fatima Cardoso, Murat Akdere, Liz Santarsiero, Fen Ye, Zuzanna Angehrn, Komal Jhaveri
Read the full article.
You can also read:
Germline Multigene Testing May Identify Higher-Risk Invasive Lobular Breast Cancer
